Pure Global AI
NCT06391827Not yet recruiting

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

A Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Orally Administered DA-7503 After Single and Multiple Ascending Dose Regimens in Healthy Adult and Elderly Participants
Dong-A ST Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
DA-7503 Single dose
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Dong-A ST Co., Ltd.
Location
Seoul, South Korea
Timeline & enrollment
Phase
Phase 1
Start date
May 07, 2024
End date
May 31, 2025
Enrollment
72 participants
Primary outcome

Pharmacokinetics of DA-7503 single dose oral administration,Pharmacokinetics of DA-7503 single dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration,Pharmacokinetics of DA-7503 multiple dose oral administration

Summary

This is a double-blind, placebo-controlled, randomized, phase 1 study to evaluate safety,
 tolerability, and pharmacokinetics of orally administered DA-7503 after single and multiple
 ascending dose regimens in healthy adult and elderly participants

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06391827
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06391827 through Pure Global AI's free database. This Phase 1 trial is sponsored by Dong-A ST Co., Ltd. and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.